Xiao-Feng Li, M.D., Ph.D.
Xiao-Feng Li, M.D., Ph.D.
Assistant Professor of Radiology
Department of Radiology
University of Louisville Hospital
530 South Jackson Street
Louisville KY 40202
Academic Office (502) 852-5875
Email: xiao-feng.li@louisville.edu
Education
Norman Bethune University of Medical Sciences
M.D.
Changchun, China
Kanazawa University Graduate School of Medical Sciences
Ph.D. in medical sciences (nuclear medicine)
Kanazawa, Japan
Postgraduate training
Harbin Medical University the Second Affiliated Hospital
Harbin, China
Nuclear medicine residency 1993-1998
Kanazawa University Hospital
Kanazawa, Japan
Nuclear medicine fellowship 1999-2003
Memorial Sloan-Kettering Cancer Center
New York NY
Molecular imaging research fellow, 2003-2008
Memorial Sloan-Kettering Cancer Center,
Nuclear medicine service, Department of Radiology
New York NY
PET/CT obsersership, 2008-2009
Research interests
- 18F-FDG uptake mechanism in metastases
- Animal models of metastases
- Molecular imaging cancers and metastases
- Study hypoxia, angiogenesis and cancer cells-stroma interaction in metastases of lung cnacer, coloretal cancer and breast cancer
- Experimental therapy of micrometastases
Honors and Awards
Memorial Kanahara Award, 1999
Asia and Oceania Distinguished Young Investigator Award, 2001
Academic Society Service and memberships
Member of Japanese Society of Nuclear Medicine 1999-2003
Member of New York Academic of Sciences 2003-
Member of Society of Nuclear Medicine 2005-
Member of Radiation Research Society 2006
Chairman of advisory board, Chinese American Society of Nuclear Medicine (2009-2011)
President-elected, Chinese American Society of Nuclear Medicine (2009-2011)
Reviewer of Neoplasia (since 2004), Cancer Biotherapy and Radiopharmaceuticals (since 2005),
Radiation Research (since 2007), Medical Physics (since 2007), Cancer Letters (since 2008)
Publications (*corresponding author)
1. Li XF*, Ma Y, Sun X, Humm JL, Ling CC, O’Donoghue JA. High 18F-fluoro-deoxyglucose (18F-FDG) uptake in microscopic peritoneal tumors requires physiological hypoxia. J Nucl Med (2010 In Press).
2. Li XF*, Sun X, Ma Y, Suehiro M, Zhang M, Russell J, Humm JL, Ling CC and O’Donoghue JA. Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography. Eur J Nucl Med Mol Imaging. 2009 Nov 17. [Epub ahead of print]DOI: 10.1007/s00259-009-1310-y
3. Yang KM, Russell J Lupu ME, Cho HJ, Li XF, Koutcher JA and Ling CC. Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model. Cancer Biol Ther 2009 Oct;8(20):1940-6.
4. Sun X, Li XF, Russell J, Xing L, Urano M, Li GC, Humm JL, Ling CC. Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistry. Radiother Oncol. 2008;88:269-76 (cover image).
5. Li XF*, O’Donoghue JA. Hypoxia in microscopic tumors. Cancer Letters 2008; 264: 172-180 (invited review).
6. Zhang M, Chen Q, Li XF, O’Donoghue JA, Ruan S, Zanzonico P, Ling CC, Humm JL. Image deconvolution in digital autoradiography: a preliminary study. Medical Physics 2008; 35: 522-530
7. Li XF*, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue JA. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res 2007 Aug 15;67(16):7646-53 (cover image).
8. Li Y, Li XF*, Ma Y, Fang N, Russell J, Ma D, Sun X, Han X, Yang H, Kinuya S. Changes in the levels of CD4+ and CD8+ T lymphocytes after strontium-89 chloride therapy for painful bone metastases in patients correlate with treatment efficacy. Cancer Biother Radiopharm. 2007 Jun;22(3):367-73
9. Shin KH, Diaz-Gonzalez JA, Russell J, Chen Q, Burgman P, Li XF and Ling CC. Detecting Changes in Tumor Hypoxia with Carbonic Anhydrase IX and Pimonidazole. Cancer Biol Ther. 2007 Jan;6(1):70-5 (cover image).
10. Li XF*, Zanzonico PB, Ling CC and O’Donoghue JA. Visualization of experimental lung and bone metastases in live nude mice by X-ray micro-computed tomography. Technol Cancer Res Treat 2006; 5: 147-55.
11. Kinuya S, Li XF, Bai J, Yokoyama K, Michigishi T and Tonami N. Prediction of Therapeutic Responses to Chemotherapy and Monitor of Effects of MDR-Modulation with Radiotracers in Malignant Tumors (book chapter). In: Christopher V. Aiello, edtor. Multidrug Resistance-Associated Proteins. New York: Nova Science Publishers. 2006
12. Kinuya S, Li XF, Yokoyama K, Mori H, Shiba K, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N. Limitations of (99m)Tc tetrofosmin in assessing reversal effects of verapamil on the function of multi-drug resistance associated protein 1. Nucl Med Commun. 2004; 25: 585-9.
13. Kinuya S, Li XF, Yokoyama K, Mori H, Shiba K, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N. Hypoxia as a factor for Ga-67 accumulation in tumor cells. Nucl Med Commun 2004; 25: 49-53
14. Kinuya S, Li XF, Yokoyama K, Mori H, Shiba K, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N. Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy. Cancer Sci. 2003; 94: 650-4.
15. Kinuya S, Li XF, Yokoyama K, Mori H, Shiba K, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N. Local delivery of 131I-MIBG to treat peritoneal neuroblastoma. Eur J Nucl Med Mol Imaging. 2003;30: 1246-50.
16. Li XF, Taki J, Kinuya S, Higuchi T, Konishi S, Hwang EH, Shuke N, Nakajima K, Tonami N. Asialoglycoprotein receptor concentration in tumour-bearing livers and its fate early after their sectorial resection. Ann Nucl Med 2003; 17: 489-493.
17. Kinuya S, Li XF, Yokoyama K, Mori H, Shiba K, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N. Reduction of 99mTc-sestamibi and 99mTc-tetrofosmin uptake in MRP-expressing breast cancer cells under hypoxic conditions is independent of MRP function. Eur J Nucl Med Mol Imaging 2003; 30:1529-1531.
18. Kinuya S, Yokoyama K, Li XF, Bai J, Watanabe N, Shuke N, Takayama T, Bunko H, Michigishi T, Tonami N. Hypoxia-induced alteration of tracer accumulation in cultured cancer cells and xenografts in mice: implications for pre-therapeutic prediction of treatment outcomes with 99mTc-sestamibi, 201Tl chloride and 99mTc-HL91.Eur J Nucl Med Mol Imaging. 2002; 29:1006-1011.
19. Li XF, Kinuya S, Yokoyama K, Koshida K, Mori H, Shiba K, Watanabe N, Shuke N, Michigishi T, Tonami N. Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells. Eur J Nucl Med Mol Imaging. 2002; 29: 1669-74.
20. Li XF, Kinuya S, Yokoyama K, Konishi S, Ma YY, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N.Technetium-99m-tetrofosmin would be a substrate for multidrug resistance-associated protein (MRP): comparison between a leukemia cell line with high MRP gene expression and its parental cell line. Cancer Biother Radiopharm. 2001;16: 17-23 (editorial comment in Cancer Biother Radiopharm. 2001;16:1-7).
21. Kinuya S, Yokoyama K, Konishi S, Li XF, Watanabe N, Shuke N, Takayama T, Bunko H, Michigishi T, Tonami N. Improved response of colon cancer xenografts to radioimmunotherapy with pentoxifylline treatment. Eur J Nucl Med. 2001; 28: 750-5.
22. Kinuya S, Yokoyama K, Konishi S, Li XF, Watanabe N, Shuke N, Aburano T, Takayama T, Michigishi T, Tonami N. Increased uptake of 99mTc-HL91 in tumor cells exposed to X-ray radiation. Ann Nucl Med. 2000;14: 139-41.
